Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983978 | 0.80 | CFTR (0.40) | ALDH1A1PKMKMT2APOLB | |
| SCHEMBL16637048 | 0.80 | NPSR1 (0.41) | ALDH1A1KDM4EPKMKMT2A | |
| SCHEMBL23366909 | 0.77 | CYP1A2 (0.32) | KDM4E | |
| SCHEMBL5113693 | 0.77 | GSK3B (0.40) | KDM4E | |
| SCHEMBL16637166 | 0.76 | HDAC4 (0.44) | — | |
| Hydrochloric Acid SCHEMBL23354097 | 0.75 | LMNA (0.33) | KDM4E | |
| SCHEMBL23354458 | 0.72 | ALDH1A1 (0.33) | ALDH1A1KDM4EPKMKMT2A | |
| SCHEMBL10856198 | 0.71 | — | — | |
| SCHEMBL23354538 | 0.71 | MEN1 (0.31) | KMT2A | |
| SCHEMBL12791561 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1836203-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | ALDH1A1 1109/4885KDM4E 2834/4885PKM 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.